長春新堿作為臨床一線廣譜化療藥物廣泛用于實(shí)體瘤的治療，由于存在藥物半衰期短、神經(jīng)系統(tǒng)和胃腸道毒性強(qiáng)等缺點(diǎn)，使其臨床應(yīng)用受到限制。因此，提高長春新堿的腫瘤靶向性、延長體內(nèi)滯留時(shí)間，將其制備成新型給藥系統(tǒng)具有重要意義。近十年來國內(nèi)外關(guān)于長春新堿的新劑型研究主要有納米粒、脂質(zhì)體、微泡、微球等，這些新劑型提高了長春新堿生物利用度，使其具有良好的緩控釋能力或腫瘤靶向能力。針對(duì)長春新堿抗腫瘤新型給藥系統(tǒng)的研究做一綜述，為合理開發(fā)長春新堿新劑型提供理論依據(jù)。

Vincristine is widely used in the treatment of solid tumors as a clinical first-line broad-spectrum chemotherapy drug. However, its clinical application is limited due to some shortcomings, such as short half-life, rapid elimination, strong toxicity of nervous system and gastrointestinal tract. Therefore, it is of great significance to prepare vincristine into a new drug delivery system to improve the tumor targeting of vincristine and prolong the retention time in vivo. The research on new drug delivery system of vincristine in recent ten years is reviewed, including nanoparticles, liposomes, microvesicle and microspheres, which had improved the bioavailability of vincristine and made it good controlled release ability or tumor targeting ability, and the research on new drug delivery system of vincristine is reviewed to provide theoretical basis for the rational development of new formulations of vincristine.

R979.1;R944

江蘇省蘇州市產(chǎn)業(yè)技術(shù)創(chuàng)新專項(xiàng)（SYSD2017165）